Novel Insights into Interstitial Lung Disease Diagnostics and Treatment

A special issue of Journal of Respiration (ISSN 2673-527X).

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 2794

Special Issue Editors

Pneumology Department, Respiratory Clinical Institute, Hospital Clinic, IDIBAPS-University of Barcelona, University of Barcelona, 08007 Barcelona, Spain
Interests: interstitial lung diseases; idiopathic pulmonary fibrosis; sarcoidosis

E-Mail Website
Assistant Guest Editor
Pre-Doctoral Researcher, Pneumology Department, Respiratory Clinical Institute, Hospital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain
Interests: interstitial lung diseases; idiopathic pulmonary fibrosis; autoimmune diseases

Special Issue Information

Dear Colleagues,

In recent years, interstitial lung diseases (ILD) have presented an amazing development. The different international consensus have made it possible to clarify the different types of ILDs and optimal therapies, especially for idiopathic pulmonary fibrosis (IPF). Recent clinical trials have permitted the use of nintedanib and pirfenidone to reduce the progression of fibrotic disease. Additionally, the development of new techniques (e.g., cryobiopsy) and the multidisciplinary discussion have been definitive in the progress of diagnosis accuracy. However, many areas are currently in development. The study of different biologic pathways involved in pulmonary fibrosis is currently under investigation and new drugs are being tested. The development of the “fibrotic pulmonary phenotype“ definition in recent years and the beneficial effects of antifibrotics in this group has been one of the main recent advances in the field. This recent research has brought the ILD field into a novel and exciting moment. This Special Issue of Journal of Respiration aims to bring together current research and opinions on new concepts in diagnosis and treatment of interstitial lung diseases.

Dr. Jacobo Sellarés-Torres
Dr. Fernanda Hernandez
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Respiration is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • interstitial lung diseases
  • pulmonary fibrosis
  • antifibrotic therapies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1848 KiB  
Article
Correlations between Volumetric Capnography and Automated Quantitative Computed Tomography Analysis in Patients with Severe COPD
J. Respir. 2022, 2(1), 13-24; https://doi.org/10.3390/jor2010002 - 07 Feb 2022
Viewed by 1995
Abstract
Background: In chronic obstructive pulmonary disease (COPD), morphological analysis made by computed tomography (CT) is usually correlated with spirometry as the main functional tool. In this study, quantitative CT analysis (QCT) was compared with volumetric capnography (VCap), alongside spirometry and the 6-min walk [...] Read more.
Background: In chronic obstructive pulmonary disease (COPD), morphological analysis made by computed tomography (CT) is usually correlated with spirometry as the main functional tool. In this study, quantitative CT analysis (QCT) was compared with volumetric capnography (VCap), alongside spirometry and the 6-min walk test (6MWT). Methods: Twenty-seven patients with severe/very severe COPD were included, compared with nineteen control subjects. All participants performed spirometry and chest high resolution CT scans that were analyzed with fully-automated software. The COPD group was also submitted to VCap and 6MWT. Results: COPD patients (65.07 ± 8.25 years) showed an average FEV1 of 1.2 L (44% of the predicted) and the control group (34.36 ± 8.78 years). VCap × QCT: positive correlations were observed with bronchial wall thickening and negative correlations with diameter and area of the bronchial lumen. Spirometry × QCT: positive correlations were observed between post-BD FVC, FEV1 and FEF 25–75% and diameter and luminal area of the airways and FVC and lung and vascular volumes (emphysema). Negative correlation was observed between post-BD FVC and FEV1 when compared with Pi10 (internal perimeter of 10 mm). 6MWT vs. QCT: negative correlations were observed between the distance covered with relative wall thickness (airways) and vascular volume and peripheral vascular volume (vasculature). Conclusion: Relevant correlations between QCT and pulmonary function variables were found, including the VCap, highlighting the importance of structural analysis in conjunction with a multidimensional functional assessment. This is the first study to correlate airway and parenchyma QCT with VCap. Full article
Show Figures

Figure 1

Back to TopTop